SAN FRANCISCO—After securing FDA clearance for its G7 continuous glucose monitor system last month, Dexcom is ready to begin adding the U.S. to its list of launch sites across the globe this quarter.
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results